Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR25617936

— · E

86103798-60e9-5c82-b03e-dbfe2a04e5bf

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
  • TGF_BETA_SIGNALING+0.440
  • HYPOXIA+0.430
  • ANGIOGENESIS+0.390
  • GLYCOLYSIS+0.340
  • APICAL_JUNCTION+0.290
  • PROTEIN_SECRETION+0.290
  • MTORC1_SIGNALING+0.280
  • WNT_BETA_CATENIN_SIGNALING+0.260
  • UV_RESPONSE_DN+0.250

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.430
  • ESTROGEN_RESPONSE_EARLY-0.310
  • INTERFERON_GAMMA_RESPONSE-0.290
  • ESTROGEN_RESPONSE_LATE-0.270
  • ALLOGRAFT_REJECTION-0.180
  • DNA_REPAIR-0.150
  • FATTY_ACID_METABOLISM-0.140
  • P53_PATHWAY-0.140
  • APOPTOSIS-0.130
  • IL2_STAT5_SIGNALING-0.080

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120110025.TNBC
breast-umap@18
—E0.841
2SRR25617891
breast-umap@18
—E0.809
3SRR2932813
head-neck@1
——0.809
4TCGA-AR-A24Q-01A-12R-A169-07
breast-umap@18
—E0.805
5TCGA-A7-A13D-01A-13R-A277-07
breast-umap@18
—E0.800
6TCGA-BH-A0AV-01A-31R-A115-07
breast-umap@18
—E0.769
7MBCProject_2290_T2_RNA
breast-umap@18
—E0.767
8MNG56
mng-umap@100
——0.765
9TCGA-A7-A13D-01A-13R-A12P-07
breast-umap@18
—E0.763
10TCGA-60-2708-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.759

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.540Inavolisib— uncovered
TGF_BETA_SIGNALING0.440Inavolisib— uncovered
HYPOXIA0.430Idelalisib— uncovered
ANGIOGENESIS0.390Remibrutinib— uncovered
GLYCOLYSIS0.340Inavolisib— uncovered
APICAL_JUNCTION0.290Inavolisib— uncovered
PROTEIN_SECRETION0.290Remibrutinib— uncovered
MTORC1_SIGNALING0.280Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.260Inavolisib— uncovered
UV_RESPONSE_DN0.250Inavolisib— uncovered
G2M_CHECKPOINT0.230Inavolisib— uncovered
KRAS_SIGNALING_UP0.230Inavolisib— uncovered
COAGULATION0.220Binimetinib— uncovered
MYC_TARGETS_V10.200Inavolisib— uncovered
HEDGEHOG_SIGNALING0.190Inavolisib— uncovered
E2F_TARGETS0.170Inavolisib— uncovered
MITOTIC_SPINDLE0.170Inavolisib— uncovered
MYOGENESIS0.160Inavolisib— uncovered
NOTCH_SIGNALING0.140Inavolisib— uncovered
MYC_TARGETS_V20.100Idelalisib— uncovered